ZSTK474 0419 1225497-78-8 (Rigosertib Sodium(EZ))

1225497-78-8 (Rigosertib Sodium(EZ))

Nishimura H

Smiles: O[C@@H]1CN(CC1)C(=O)NC1C=NN2C=CC(=NC2=1)N1CCC[C@@H]1C1=CC(F)=CC=C1F

are the most frequent genetic alterations in acute myeloid leukemia (AML) and occur in approximately one-third of AML cases

UNII-R1ZW9H43ZJ

ZSTK474 0419 1225497-78-8 (Rigosertib Sodium(EZ))ZSTK474 is a novel orally applicable phosphoinositide 3 kinase specific inhibitor that strongly inhibits cancer cell proliferation. Combination treatment using X rays then ZSTK474 given orally for 8 days, starting 24h post irradiation, significantly enhanced cell growth inhibition. The combined effect was also observed for clonogenic survival with continuous ZSTK474 treatment. Western blot analysis showed enhanced phosphorylation of Akt and GSK 3 by X